Pacific Edge Limited (NZSE: PEB)
Health Care · Biotechnology · NZ
NZ$0.25
-3.85% today · +74.8% 1Y
Pacific Edge Limited (NZSE: PEB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $185.45M and employs 114 people.
Over the last twelve months the share price has gained 74.8%, trading between 0.13 and 0.34.
Tweenvest scores Pacific Edge Limited across four factors: quality 27/100, value 50/100, growth 57/100. Its strongest factor is growth.
PEB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $185.45M
- Revenue (TTM)
- $7.44M
- P/E
- —
- EPS
- -0.04
- Dividend yield
- —
- Beta (5Y)
- 0.82
- 52-week high
- NZ$0.34
- 52-week low
- NZ$0.13
- Avg volume (3M)
- —
- Shares outstanding
- 1.24B
- Employees
- 114
- Next earnings
- —
About Pacific Edge Limited
Based in Dunedin, New Zealand, Pacific Edge Limited, established in 2001, operates as a cancer diagnostics firm. The company's core mission involves the research, development, and commercialization of advanced diagnostic and prognostic tools aimed at the early identification and ongoing management of various cancers. Its diagnostic solutions are accessible in New Zealand, the United States, Australia, and Singapore, with operations structured across Commercial and Research segments. A key offering is the Cxbladder suite, a collection of genomic urine tests specifically designed for detecting and managing bladder cancer. Within this suite, Cxbladder Resolve aids in identifying patients likely to present with more aggressive or advanced bladder cancer. Cxbladder Triage helps pinpoint individuals with haematuria who exhibit a low probability of bladder cancer, while Cxbladder Detect offers a non-invasive method for identifying bladder and other urinary tract cancers. Furthermore, Cxbladder Monitor facilitates continuous surveillance for disease recurrence in bladder cancer patients. Beyond its focus on bladder cancer, Pacific Edge is actively developing additional diagnostic innovations. These include Cxcolorectal, a prognostic gene signature for assessing outcomes in patients diagnosed with stage II or stage III colorectal cancers, alongside pipeline products targeting gastric, endometrial cancers, and melanoma.
- ISIN
- NZPEBE0002S1
- Founded
- 2001
- Listed since
- Nov 23, 2003
- Exchange
- New Zealand Stock Exchange
- Currency
- NZD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.